Offshore law firm, Mourant Ozannes, has advised leading European private equity firm Cinven on its £2.3 billion sale of Amdipharm Mercury Limited (AMCo), a niche specialty pharmaceuticals group, to TSX/Nasdaq-listed Concordia Healthcare Corporation (Concordia).
Mourant Ozannes acted for private equity firm Cinven when it acquired Amdipharm and Mercury Pharma in 2012 to create AMCo and since then has advised AMCo on various bolt-on acquisitions and related financings.
The Mourant Ozannes team which advised on the deal was led by partner James Hill and senior associate Andrew Salisbury. Mourant Ozannes provided Jersey law advice to Cinven on all aspects of the transaction and worked closely with leading international law firm Clifford Chance, who advised Cinven on matters of English law.
Commenting on the deal, James Hill said: "This is a major strategic deal for both Cinven and Concordia and we are delighted to have been part of it. We worked with Clifford Chance and Cinven on the establishment of AMCo in 2012 and since then we have assisted AMCo with a number of acquisitions and financings. There were various aspects to this deal which showcase our abilities as a leading offshore law firm."